Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADXS31-142
- Development stage
- Phase 2
- Lead developer
- Advaxis
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
ADXS31-142 is a live attenuated, bioengineered immunotherapy based on the bacterium *Listeria monocytogenes*. It is designed to secrete a fusion protein composed of a truncated listeriolysin O (tLLO) and human prostate-specific antigen (PSA), thereby stimulating an immune response against PSA-expressing tumor cells. The drug acts as a cancer vaccine and has been investigated both as monotherapy and in combination with pembrolizumab for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its mechanism involves activating the immune system to recognize and attack prostate cancer cells expressing PSA[1][2][3][4].
- Other names
- Listeria monocytogenes-LLO-PSA vaccineLm-LLO immunotherapy targeting PSA
02
Targets
PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on ADXS31-142.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADXS31-142.